Skip to main content
Premium Trial:

Request an Annual Quote

Kreatech, LUMC Co-developing Tumor Tests

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Dutch molecular diagnostics shop Kreatech Diagnostics announced today a co-development deal with Leiden University Medical Center directed at fluorescent in situ hybridization probes for genetic targets in bone and soft tissue tumors.

Biomarkers resulting from research conducted at LUMC will be used to design and commercialize diagnostic tests for the differential diagnosis of tumors and as companion diagnostics, Kreatech said. LUMC will validate the probes and Kreatech will manufacture and commercialize them.

Further terms of the deal were not disclosed.

The first three probes, which will focus on sarcoma diagnostics, are expected to be launched this year. The two partners also intend to develop a range of FISH probes for the pathology field.

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.